Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

The Quietude Study: Quetiapine Use for Agitated Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01363310
Recruitment Status : Terminated (Termination of sponsorship)
First Posted : June 1, 2011
Last Update Posted : January 8, 2014
Information provided by:
Physicians Research And Education Network

Brief Summary:

Most individuals with major depressive disorder manifest clinically significant agitation. Concurrent agitation in a depressed individual is associated with an intensification of mood symptoms, decreased probability of recovery, increased recurrence risk, suicidality, and increased medical-service utilization. The occurrence of anxiety/agitation phenomenology in the depressed patient often invites the need for augmentation strategies (e.g. atypical antipsychotics, benzodiazepines, etc.) and complicated polypharmacy regimens. Moreover, individuals with major depressive disorder often report worsening of symptom severity, irritability, hostility, dysphoria, and significant subjective distress (This response pattern is similar to individuals with bipolar disorder).

Results from large research studies provide evidence indicating that quetiapine is capable of offering clinically significant multidimensional symptom relief in bipolar depression. Moreover, results from several trials in major depressive disorder and generalized anxiety disorder have established the efficacy of quetiapine therapy for unipolar depression and anxiety syndromes. So far, no atypical antipsychotic agent has been evaluated specifically for the treatment of agitated depression.

In this study, it is hypothesized that persons with major depressive disorder and prominent agitation (i.e. agitated depression) will exhibit a more favourable response and tolerability profile to quetiapine XR when compared to escitalopram.

Condition or disease Intervention/treatment Phase
Depression With Prominent Agitation Drug: Quetiapine XR Drug: Escitalopram Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-Centre, Double-Blind, Randomised, Parallel Group, Escitalopram Controlled Phase III-B Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR TM) as Monotherapy in the Treatment of Adult Patients With Agitated Major Depressive Disorder
Study Start Date : October 2010
Actual Primary Completion Date : January 2013
Actual Study Completion Date : February 2013

Arm Intervention/treatment
Active Comparator: Quetiapine XR Drug: Quetiapine XR
Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)
Other Name: Seroquel XR

Active Comparator: Escitalopram Drug: Escitalopram
Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)

Primary Outcome Measures :
  1. Change from baseline to endpoint in the Hamilton Depression Rating Scale 17-Item (HAMD-17) total score [ Time Frame: Day 1, Day 57 ]
    A tool to assess the range of symptoms of depression

Secondary Outcome Measures :
  1. Change in anxiety factor score on the Hamilton Depression Rating Scale 17-item (HAMD-17) from baseline to endpoint [ Time Frame: Day 1, Day 57 ]
    A tool to assess the range of symptoms of depression

  2. Change from baseline to endpoint in Hamilton Anxiety Rating Scale (HAMA) total score [ Time Frame: Day 1, Day 57 ]
    A tool to measure severity of symptoms of anxiety

  3. Change in Clinical Global Impression score from baseline to endpoint [ Time Frame: Screening Visit, Day 1, Day 8, Day 15, Day 29, Day 43, Day 57 ]
    A tool to assess illness severity, improvement and response to treatment

  4. Change from baseline to endpoint in Sheehan Disability Scale (SDS) sub-scales and total score [ Time Frame: Day 1, Day 57 ]
    A tool to assess functional impairment

  5. Change in Hamilton Depression Rating Scale 17-item (HAMD-17) sleep disturbance factor score on the from baseline to endpoint [ Time Frame: Day 1, Day 57 ]
    A tool to assess the range of symptoms of depression

  6. Change in Hamilton Anxiety Rating Scale (HAMA) somatic and psychic anxiety factor scores from baseline to endpoint [ Time Frame: Day 1, Day 57 ]
    A tool to measure severity of symptoms of anxiety

  7. Change from baseline in the Sex Functioning Questionnaire (Sex FX) [ Time Frame: Day 1, Day 57 ]
    A tool to assess sexual functioning

  8. Change in blood pressure and heart rate from baseline to end of treatment [ Time Frame: Day 1, Day 57 ]
  9. Change in weight, BMI, waist circumference from baseline to end of treatment [ Time Frame: Day 1, Day 57 ]
  10. Change in findings from physical examination from baseline to end of treatment [ Time Frame: Screening, Day 57 ]
  11. Tabulation of spontaneous adverse events [ Time Frame: Day 1, Day 57 ]
  12. Tabulation of clinical haematology and chemistry results [ Time Frame: Screening, Day 57 ]
  13. Incidence of premature study withdrawal due to inadequate control of depressive symptoms
  14. Proportion of patients with HAM-D Item 3 score > 2 at any time after randomization or adverse events of suicidality/suicidal ideation/suicide attempts/suicide completion [ Time Frame: Day 1, Day 57 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female
  • Age 18 to 65
  • Outpatient at enrolment
  • A diagnosis of major depressive disorder
  • Baseline HAMD-17 score > 20 and HAMD Item1 score > 2 both at enrolment and baseline
  • Significant agitation
  • CGI-S score > 4 at screening and baseline
  • Negative serum pregnancy test at enrolment and use of a reliable method of birth control during the study
  • Able to understand and comply with the requirements of the study
  • Able and willing to give meaningful informed written consent

Exclusion Criteria:

  • Another Axis I diagnosis of primary focus within 6 months of enrolment
  • Axis II disorder causing impact on current diagnosis
  • Current depressive episode <4 weeks, or >12 months
  • Substance or alcohol abuse or dependency as defined by DSM IV within 6 months of enrolment
  • Any pervasive developmental disorder or dementing disorder
  • Treatment with other antipsychotics, mood stabilizer or other psychoactive drugs less than 7 days prior to randomization
  • Treatment with fluoxetine less than 28 days prior to baseline
  • Treatment with MAO inhibitors, anxiolytic drugs in excess of 2 mg lorazepam equivalents/day.
  • Insufficient response to more than two antidepressants during the index episode prior to study involvement
  • Known lack of antidepressant response to quetiapine at a dose of at least 50 mg/day x 4 weeks
  • Known lack of antidepressant response to escitalopram at a dose of at least 10 mg/day
  • Known intolerance or hypersensitivity to quetiapine or escitalopram
  • Treatment with Electroconvulsive therapy within 90 days prior to baseline
  • Use of Potent P450 3A4 inhibitors or inducers within 14 days of baseline
  • AST & ALT ≥ 3X ULN
  • TSH ≥ 10% ULN
  • Unstable medical condition
  • Medical condition the would affect absorption, distribution, metabolism or excretion of study treatment
  • Significant ECG abnormalities
  • Pregnancy or lactation
  • Patients with increased suicidal risks, HAM-D item 3 ≥3 or have made a suicide attempt within the past 6 months.
  • Patients who, in the investigators opinion, will require psychotherapy (other than supportive psychotherapy) during the study period, unless psychotherapy has been ongoing for a minimum of 3 months prior to randomisation
  • A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:
  • Unstable DM defined as enrolment glycosylated haemoglobin (HbA1c) >8.5%.
  • Admitted to hospital for treatment of DM or DM related illness in past 12 weeks.
  • Not under physician care for DM.
  • Physician responsible for patient's DM care has not indicated that patient's DM is controlled.
  • Physician responsible for patient's DM care has not approved patient's participation in the study
  • Has not been on the same dose of oral hypoglycaemic drug(s) and/or diet for the 4 weeks prior to randomisation. For thiazolidinediones (glitazones) this period should not be less than 8 weeks.
  • Taking insulin whose daily dose on one occasion in the past 4 weeks has been more than 10% above or below their mean dose in the preceding 4 weeks Note: If a diabetic patient meets one of these criteria, the patient is to be excluded even if the treating physician believes that the patient is stable and can participate in the study
  • Clinically significant deviation from the reference range in clinical laboratory test results
  • An absolute neutrophil count (ANC) of 1.5 x 109 per liter
  • Those who are involved in the planning and/or conduct of the study cannot be enrolled as subjects
  • Previous enrolment or randomization in the present study
  • Participation in another medication trial within 4 weeks prior to enrolment into the study herein

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01363310

Layout table for location information
Canada, Ontario
Aggarwal and Associates Ltd
Brampton, Ontario, Canada, L6T 0G1
Aptekar Medicine Professional Corporation
Brampton, Ontario, Canada, L6W 2A4
Chatham-Kent Health Alliance
Chatham, Ontario, Canada, N7L 1B7
Fort Erie Group Family Practice
Fort Erie, Ontario, Canada, L2A 1Z3
Georgina Family Medical Centre
Keswick, Ontario, Canada, L4P 2C7
Richmond Oxford Walk-In Clinic
London, Ontario, Canada, N6A 5G6
Gerald Rockman Medicine Professional Corporation
Scarborough, Ontario, Canada, M1N 1W8
Brady Clinic
Sudbury, Ontario, Canada, P3E 1H5
Bloor-Park Medical Centre
Toronto, Ontario, Canada, M6G 1L4
Primary Care Lung
Toronto, Ontario, Canada, M6H 3M2
Manna Research
Toronto, Ontario, Canada, M9W 4L6
Sponsors and Collaborators
Physicians Research And Education Network
Layout table for investigator information
Study Director: Roger McIntyre, MD, FRCPC Physicians Research And Education Network
Layout table for additonal information
Responsible Party: Roger S. McIntyre, MD, FRCPC, Physicians' Research and Education Network Identifier: NCT01363310    
Other Study ID Numbers: D1443C00037
First Posted: June 1, 2011    Key Record Dates
Last Update Posted: January 8, 2014
Last Verified: January 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Quetiapine Fumarate
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants